ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancerShaghayegh Nouruzi, Amina Zoubeidi|JCI Insight|2024Cited by 15
Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308Shaghayegh Nouruzi, Amina Zoubeidi|Oncology Reports|2024Cited by 1